|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At the molecular level, we further revealed that FoxO1, a tumor suppressor in multiple human cancers, was transcriptionally repressed by ZBTB20.
|
25311537 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, the order of expression of these transgenes was critical, as only those cells expressing PAX3-FKHR early could form tumors.
|
19047133 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, all of the tumors with rhabdomyosarcomatous differentiation were negative for FKHR rearrangement.
|
21762516 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Within the ARMS subtype, IGF2 positivity was limited to PAX/FKHR translocation-negative tumors.
|
18788888 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein arginine methyltransferase 1 (PRMT1) may play a role in chemosensitivity/apoptosis induction via activation of the tumor suppressor forkhead box O1 (FOXO1).
|
26472729 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that <i>NKX3.1</i> functions as a tumor suppressor in HCC cells through directly up-regulating FOXO1 expression.
|
28972178 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the microarray analysis is utilized to preliminarily clarify the oncogenic molecular mechanisms regulated by NDC80 and the results suggest it may promote CRC progression partly by downregulating tumor suppressors such as dual specificity phosphatase 5 and Forkhead box O1.
|
29341479 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The level of FOXO1 in high-grade lesions was significantly lower than in low-grade lesion (P < 0.05), indicating that deficient expression of FOXO1 is involved in tumor progression and significantly associated with late-stage tumors (P < 0.05), which was further supported by clinicopathological, real-time polymerase chain reaction, and Western blotting analysis.
|
26125868 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, resveratrol-treated mice showed significant inhibition in tumor growth which was associated with reduced phosphorylation of ERK, PI3K, AKT, FOXO1 and FOXO3a, and induction of apoptosis and FOXO target genes.
|
21980390 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using immunohistochemistry and immunofluorescence to examine the expression of FOXO1 in 185 surgically resected, paraffin-embedded stage I-IV tumor samples, we observed a significant correspondence between positive staining for FOXO1 in early stage tumors and in tumors without nodal involvement; in contrast, no significant relationship was observed between FOXO1 expression and tumor status, lymphatic invasion, or venous invasion.
|
19513505 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The genome-wide analysis reveals that the PAX3-FKHR sites are (a) mostly distal to transcription start sites, (b) conserved, (c) enriched for PAX3 motifs, and (d) strongly associated with genes overexpressed in PAX3-FKHR-positive rhabdomyosarcoma cells and tumors.
|
20663909 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The xenograft study showed that FOXO1 downregulation enhanced tumor growth, microvessel areas, HIF-1α activation and vascular endothelial growth factor (VEGF) expression.
|
25761483 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326).
|
30478420 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.
|
31493794 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, these studies reveal that PAX3, PAX7 and their fusions with FKHR are each expressed in RMS tumors as a consistent mixture of functionally distinct isoforms.
|
15688409 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of dominant-negative p53, or the SV40 early region, elicits tumor formation in some of the PAX-FKHR-expressing populations.
|
18701482 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we provide a link between FOXO1 repression and PRDM1α downregulation in cHL and identify PRDM1α as a tumor suppressor in cHL.
|
25232062 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
|
30272279 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This article may serve as a guide for future research and identify FOXO1 as a potent therapeutic target in neoplasms.
|
29473160 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One major subgroup of RMS tumors (so-called "fusion-positive" tumors) carries exclusive chromosomal translocations that join the DNA-binding domain of the PAX3 or PAX7 gene to the transactivation domain of the FOXO1 (previously known as FKHR) gene.
|
25368019 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review discusses the role of PAX3-FOXO1 in ARMS tumors.
|
23432728 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show a tumor suppressor role of AKT-phosphorylated FOXO1 in the cytoplasm and suggest that this function of FOXO1 can be harnessed to overcome chemoresistance in cancer.
|
28279977 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protective effects of FoxO1:S<sup>249</sup>V were detected by the xenograft tumor formation assay.
|
30453847 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, FoxO1-negative cells formed tumor spheres in culture and developed tumors after serial adoptive transplantation into NOD/SCID mice, while the FoxO1-positive cells did not.
|
26068418 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, ALK mRNA distinguished unfavourable PAX3/7-FOXO1-positive tumours from PAX3/7-FOXO1-negative RMS (P<0.0001), and also correlated with larger tumour size (P<0.05) and advanced clinical stage (P<0.01), independently of fusion gene status.
|
24149177 |
2013 |